Sustained-release could ease treatment of glaucoma and other conditions
BOSTON, July 21 /PRNewswire-USNewswire/ -- Taking eye drops multiple times a day can be difficult for patients to do, and because of blinking and tearing, as little as 1 to 7 percent of the dose is actually absorbed by the eye. Now, researchers led by Daniel Kohane, MD, PhD, director of the Laboratory for Biomaterials and Drug Delivery at Children's Hospital Boston, have developed special contact lenses that can gradually dispense a constant amount of medication to the eye, at adjustable rates. They describe their prototype lens in the July issue of Investigative Ophthalmology and Visual Science.
Although other groups have developed drug-releasing contact lenses, none have been able to achieve a constant, steady release of substantial amounts of drug; typically, a burst of drug is delivered in the first few hours, followed by rapidly dwindling amounts that are too low to be therapeutic. Kohane, collaborator Joseph Ciolino, MD, of the Massachusetts Eye and Ear Infirmary, and colleagues at the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT) created a two-layer contact lens with an inner drug-bearing biodegradable polymer film known as PLGA. Both PLGA and pHEMA (used for the coating) have been well studied and are already approved for ocular use by the Food and Drug Administration.
In laboratory testing, the prototype lenses dispensed ciprofloxacin (an antibiotic often used in eye drops) for 30 days, the longest duration for which contact lenses are currently approved by the FDA; in some tests, the lenses continued releasing drug for up to 100 days. The amounts dispensed were sufficient to kill pathogens in a laboratory assay.
Kohane and Ciolino see applications in conditions such as glaucoma and dry-eye which require frequent daily eye drops. They have begun to test the lens in animals and plan to begin human testing as soon as possible. The technology recently won the Life Sciences track in MIT's 100K Entrepreneurship Competition.
The study was supported by the National Institute of General Medical Sciences at the National Institutes of Health, a Fight for Sight Grant-in-Aid, a Center for Integration of Medicine and Innovative Technology/Johnson & Johnson Young Investigator Award and the Boston KPro Fund, Massachusetts Eye and Ear Infirmary.
Citation: Ciolino JB, Hoare TR, Iwata NG, et al. A drug-eluting contact lens. Invest Ophthalmol Vis Sci 2009; 50:3346-52.
[Note to reporters: A photo of the lens is available from the Association for Research in Vision and Ophthalmology. Please contact Jamie Newton at 617-919-3110 or firstname.lastname@example.org to obtain the image.]
Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 500 scientists, including eight members of the National Academy of Sciences, 12 members of the Institute of Medicine and 12 members of the Howard Hughes Medical Institute comprise Children's research community. Founded as a 20-bed hospital for children, Children's Hospital Boston today is a 397-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children's also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about the hospital and its research visit: www.childrenshospital.org/newsroom.
CONTACT: Jamie Newton Children's Hospital Boston 617-919-3110 email@example.com
|SOURCE Children's Hospital of Boston|
Copyright©2009 PR Newswire.
All rights reserved